Financial News Feed

Stronger Sell Today ALXN ranks #2392 as SELL CANDIDATE. Weaker Sell
Today ALXN ranks #2392 as SELL CANDIDATE.

ALXN stock Alexion Pharmaceuticals

ALXN stock
Alexion Pharmaceuticals

Some investors may be looking to trade the trend and capitalize on strong current performers. Other investors may look to take a contrarian approach. This can involve looking for names that have been ...

Read more

Several brokerages have updated their recommendations and price targets on shares of Alexion Pharmaceuticals (NASDAQ: ALXN) in the last few weeks: 3/21/2019 – Alexion Pharmaceuticals had its “neut...

Read more

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Cerecor Inc. (NASDAQ:CERC) have been rivals in the Biotechnology for quite some time. Below is a review of each...

Read more

We are comparing Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) and Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on their profitability, institutional ownership, analyst recommendations, risk, dividends, ear...

Read more

As Biotechnology businesses, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Akari Therapeutics Plc (NASDAQ:AKTX), are affected by contrast. This especially...

Read more

We are contrasting Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Abeona Therapeutics Inc. (NASDAQ:ABEO) on their institutional ownership, earnings and valuation, profitability, risk, dividends, analy...

Read more

Big Money Sentiment increased to 1.11 in Q4 2018. It has change of 0.07, from 2018Q3's 1.04. The ratio is positive due to Alexion Pharmaceuticals, Inc....

Read more

Investors sentiment increased to 1.11 in Q4 2018. Its up 0.07, from 1.04 in 2018Q3. It is positive, as 44 investors sold ALXN shares while 167 reduced...

Read more

As Biotechnology companies, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) are our subject to contrast. And more specifically their profitability, analyst recomm...

Read more

The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Alexion Ph...

Read more

Sears Hometown & Outlet Stores Inc (SHOS) investors sentiment decreased to 0.62 in Q4 2018. It’s down -0.30, from 0.92 in 2018Q3. The ratio worsened, as 8 investment professionals started new and in...

Read more

Guggenheim restated their neutral rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research report report published on Thursday. The brokerage currently has a $135.00 price objective on ...

Read more

Following some earnings data for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), we note that the current quarter EPS consensus estimate is 2.2. This EPS estimate is using data provided by 10 sell-side a...

Read more

Iterum Therapeutics plc (NASDAQ:ITRM) and Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) are two firms in the Biotechnology that compete against each other. Below...

Read more

Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) and Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), are influenced by compare since they are both players in the Biotechnology. These factors are particularly in...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank